NCT04846842Unknown2 期
A Phase II Study of Gimatecan in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Lee's Pharmaceutical Limited0 个研究点目标入组 46 人开始时间: 2021年7月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 46
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
This phase II clinical trial studies the safety and effect of Gimatecan in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or peritoneal cancer.
The chemotherapy will be given every four weeks.This study is a single-arm, multi-center research design.
详细描述
The study had 3 phases: screening phase, treatment phase and follow-up phase. During the treatment phase, the drug will continue to be administered until the progression of disease, complete remission , unacceptable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •The subjects were able to understand the informed consent, voluntarily participate in and sign the informed consent, with good compliance and cooperation with follow-up.
- •A histopathological or cytological diagnosis of epithelial ovarian, fallopian tube or peritoneal cancer.
- •Previous systematic treatment ≤ 2 lines, and progression in platinum based regimens or recurrence within 6 months after the end of platinum regimen. 1) Imaging progression of recurrence and progression should be clearly recorded;2) Neoadjuvant + adjuvant chemotherapy with platinum regimen ≥ 6 cycles, and platinum regimen after recurrence / progression ≥ 4 cycles;3) If there is progression during the treatment of platinum based regimen, the treatment cycle is not limited;4) Recurrence / progression within 6 months after the end of neoadjuvant / adjuvant therapy is considered to have received the first-line systematic treatment.
- •Measurable cancer lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;
- •≥18 years old;
- •Eastern Cooperative Oncology Group(ECOG) performance status score 0-1;
- •Estimated life expectancy >3 months;
- •The function of important organs meets the following requirements:
- •white blood cell count (WBC) ≥ 3.0×109/L, absolute neutrophil count (ANC) ≥ 1.5×109/L, platelets ≥ 100×109/L, hemoglobin ≥ 90g/L;
- •ALT, AST≤ 2.5×ULN; liver metastasis: ALT、AST≤ 5.0×ULN;
- •serum albumin ≥ 28g/L;
- •total bilirubin ≤ 1.5×ULN;
- •serum creatinine ≤ 1.5×ULN, creatinine clearance rate ≥60 mL/min;
- •PT≤ 1.5×ULN;
- •The subjects had no history of allergy to camptothecin or its components;
- •Non surgical sterilization or female subjects of childbearing age need to use a medically approved contraceptive method after signing the informed consent, during the study treatment period and within 6 months after the end of the study treatment period; non surgical sterilization female subjects of childbearing age must have negative blood HCG test within 3 days before entering the study; and they must be in non lactation period.
- •Taking drugs orally;
- •The subjects had recovered and treatment will start more than 4 weeks after the end of previous surgery, chemotherapy, targeted therapy and radiotherapy.
排除标准
- •Subjects who have been treated previously with topotecan, Irinotecan or other topoisomerase I inhibitors;
- •Other anticancer therapy including any investigational agent within 30 days prior to the first dose of the investigational drug gimatecan;
- •Within 14 days before the first dose of the investigational drug gimatecan, any active infection requiring systemic anti infective treatment;
- •Subjects with a history of major gastrointestinal surgery (e.g., total gastrectomy, small bowel resection) or gastrointestinal dysfunction that may alter drug absorption and activity in vivo;
- •Severe cardiovascular disease, such as NYHA grade 3-4 heart failure;
- •Patients who have been treated previously with intravenous or oral drugs that affect CYP isoenzymes within 7 days prior to the first dose of the investigational drug gimatecan;
- •A history of immunodeficiency (including a positive HIV test result);Presence of active hepatitis B , hepatitis C (positive for hepatitis C antibody, and HCV-RNA levels higher than the lower limit of the assay);
- •Pleural effusion, pericardial effusion or ascites with clinical symptoms can not be controlled by puncture drainage or other treatment;
- •Subjects with hereditary or acquired bleeding tendency (hemophilia, thrombocytopenia, etc.), interstitial pneumonia or pulmonary fibrosis, and active tuberculosis (whether or not treated) in the past year;
- •Vaccinated with live attenuated vaccine within 4 weeks;
- •Subjects had other active malignancies within 5 years before the first dose of the investigational drug gimatecan;
- •Subjects with active meningeal metastasis or uncontrollable and untreated brain metastasis.
- •Other considered unsuitable for the study.
研究组 & 干预措施
Gimatecan group
Experimental
In Phase II study, patients will receive gimatecan at fixed dose level (0.8mg/m2/d, oral, every 4 weeks) until progressive disease (PD)、complete remission（CR）).
干预措施: Gimatecan (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: To evaluate objective response rate every 8 weeks after the initiation of chemotherapy, up to 24 months.
Percentage of patients with objective response assessed by best overall response (BOR) and independent review committee （IRC） of either complete response(CR) or partial remission(PR) will be reported.
次要结局
- Duration of Response (DoR)(From date of randomization until the date of death from any cause or the date of last follow-up whichever came first, assessed up to 24 months.)
- Disease control rate (DCR)(To evaluate disease control rate every 8 weeks after the initiation of chemotherapy, up to 24 months.)
- Overall survival (OS)(From date of randomization until the date of death from any cause or the date of last follow-up whichever came first, assessed up to 24 months.)
- Progression free survival (PFS)(From date of randomization until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 24 months.)
研究者
相似试验
Unknown
2 期
A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic CancerPancreatic CancerNCT04571489Lee's Pharmaceutical Limited60
已完成
2 期
A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast CancerBreast CancerNCT00191451Eli Lilly and Company150
进行中（未招募）
2 期
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic AlterationsInfiltrating Bladder Urothelial CarcinomaStage II Bladder Urothelial CarcinomaStage III Bladder Urothelial CarcinomaNCT03609216Alliance for Clinical Trials in Oncology237
进行中（未招募）
不适用
Phase II study of gimatecan (ST 1481) as salvage treatment in patients with advanced breast cancer after anthracycline /taxanes-based chemotherapy regimeadvanced breast cancerLevel: LLTClassification code 10006285EUCTR2004-005106-79-ESSigma Tau industrie Farmaceutiche Riunite Spa43
Unknown
1 期
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerOvarian Epithelial CancerFallopian Tube CancerPrimary Peritoneal CancerNCT04029909Lee's Pharmaceutical Limited12